Flputnam Investment Management Co. Increases Holdings in Stryker Corporation $SYK

Flputnam Investment Management Co. lifted its stake in shares of Stryker Corporation (NYSE:SYK) by 64.1% in the 2nd quarter, HoldingsChannel reports. The firm owned 137,133 shares of the medical technology company’s stock after buying an additional 53,552 shares during the quarter. Flputnam Investment Management Co.’s holdings in Stryker were worth $43,175,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of SYK. VanderPol Investments L.L.C. raised its holdings in Stryker by 1.4% during the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after acquiring an additional 28 shares during the period. KCM Investment Advisors LLC increased its holdings in shares of Stryker by 1.5% in the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock worth $653,000 after buying an additional 28 shares during the last quarter. Rossby Financial LCC lifted its stake in Stryker by 6.6% in the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after purchasing an additional 28 shares during the last quarter. Tcfg Wealth Management LLC raised its position in Stryker by 2.7% during the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after purchasing an additional 29 shares during the last quarter. Finally, ICW Investment Advisors LLC lifted its holdings in Stryker by 0.6% in the fourth quarter. ICW Investment Advisors LLC now owns 5,096 shares of the medical technology company’s stock worth $1,791,000 after buying an additional 30 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. JPMorgan Chase & Co. cut their target price on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. BMO Capital Markets began coverage on Stryker in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price objective on the stock. Leerink Partners dropped their target price on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Stryker in a report on Friday, July 31st. Finally, Raymond James Financial set a $370.00 target price on Stryker in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $386.28.

Insider Activity

In other news, insider Debra King sold 826 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. The trade was a 11.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Dylan Bram Crotty sold 441 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the sale, the insider owned 6,102 shares of the company’s stock, valued at $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is currently owned by insiders.

Stryker Trading Up 2.9%

NYSE SYK opened at $331.32 on Friday. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86. The stock has a market cap of $127.08 billion, a P/E ratio of 34.33, a P/E/G ratio of 2.11 and a beta of 0.76. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The company has a fifty day simple moving average of $329.10 and a two-hundred day simple moving average of $331.47.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same quarter last year, the business posted $3.13 EPS. The company’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.